Mycobacterium w (Mw) drug to be tried on 40 patients at three hospitals to check its efficacy: PGIMER Director

Prof Dr Jagat Ram, Director of PGIMER, Chandigarh on Sunday said the safety trial of mycobacterial w (Mw) drug has been successfully completed but its actual trial will be conducted on 40 patients in PGI Chandigarh along-with AIIMS-Delhi and Bhopal.

Coronavirus, COVID 19 Vaccine, Clinical Trial, PGIMER, Dr Prof Jagat Ram, AIIMS Delhi and Bhopal, Vaccine to Be Tried on 40 Patients, Top National News, English News, True Scoop News- True Scoop
PGIMER doctors used Mw as an adjunct while treating the critically ill patients of coronavirus and plans to use it further if required.

Mw was originally developed as an immunomodulator for leprosy which acts through the toll-like receptor pathway and enhances host-T cell responses. Mw can potentially decrease the cytokine storm seen among COVID-19 patients, and may thus be of potential benefit in managing these patients and decreasing mortality.

A study is being conducted by PGIMER-Chandigarh, AIIMS-Delhi, and AIIMS-Bhopal to analyse the use of Mw--heat-killed mycobacterium indicus pranii-as an adjunct to the treatment of critically ill COVID-19 patients. 


In a recently concluded multi-centre trial, the PGIMER found that Mw reduces mortality in ICU patients with severe sepsis and it can potentially decrease the cytokine storm seen in patients with COVID-19, and may thus be of potential benefit in managing these patients and decreasing mortality.



Trending